Tricyclic antidepressants inhibit hippocampal α7* and α9α10 nicotinic acetylcholine receptors by different mechanisms

Hugo R. Arias, Elizabeth Vázquez-Gómez, Andy Hernández-Abrego, Sofía Gallino, Dominik Feuerbach, Marcelo O. Ortells, Ana Belén Elgoyhen, Jesús García-Colunga

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The activity of tricyclic antidepressants (TCAs) at α7 and α9α10 nicotinic acetylcholine receptors (AChRs) as well as at hippocampal α7-containing (i.e., α7*) AChRs is determined by using Ca 2+ influx and electrophysiological recordings. To determine the inhibitory mechanisms, additional functional tests and molecular docking experiments are performed. The results established that TCAs (a) inhibit Ca 2+ influx in GH3-α7 cells with the following potency (IC 50 in μM) rank: amitriptyline (2.7 ± 0.3) > doxepin (5.9 ± 1.1) ∼ imipramine (6.6 ± 1.0). Interestingly, imipramine inhibits hippocampal α7* AChRs (42.2 ± 8.5 μM) in a noncompetitive and voltage-dependent manner, whereas it inhibits α9α10 AChRs (0.53 ± 0.05 μM) in a competitive and voltage-independent manner, and (b) inhibit [ 3 H]imipramine binding to resting α7 AChRs with the following affinity rank (IC 50 in μM): imipramine (1.6 ± 0.2) > amitriptyline (2.4 ± 0.3) > doxepin (4.9 ± 0.6), whereas imipramine's affinity was no significantly different to that for the desensitized state. The molecular docking and functional results support the notion that imipramine noncompetitively inhibits α7 AChRs by interacting with two overlapping luminal sites, whereas it competitively inhibits α9α10 AChRs by interacting with the orthosteric sites. Collectively our data indicate that TCAs inhibit α7, α9α10, and hippocampal α7* AChRs at clinically relevant concentrations and by different mechanisms of action.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalInternational Journal of Biochemistry and Cell Biology
Volume100
DOIs
StatePublished - 1 Jul 2018
Externally publishedYes

Fingerprint

Tricyclic Antidepressive Agents
Nicotinic Receptors
Cholinergic Receptors
Imipramine
Doxepin
Amitriptyline
Electric potential

Keywords

  • Electrophysiology
  • Hippocampal neurons
  • Mechanisms of inhibition
  • Tricyclic antidepressants
  • α7 and α9α10 nicotinic acetylcholine receptors

Cite this

Arias, Hugo R. ; Vázquez-Gómez, Elizabeth ; Hernández-Abrego, Andy ; Gallino, Sofía ; Feuerbach, Dominik ; Ortells, Marcelo O. ; Elgoyhen, Ana Belén ; García-Colunga, Jesús. / Tricyclic antidepressants inhibit hippocampal α7* and α9α10 nicotinic acetylcholine receptors by different mechanisms. In: International Journal of Biochemistry and Cell Biology. 2018 ; Vol. 100. pp. 1-10.
@article{faaa023f86714617ace7ceec04519b4b,
title = "Tricyclic antidepressants inhibit hippocampal α7* and α9α10 nicotinic acetylcholine receptors by different mechanisms",
abstract = "The activity of tricyclic antidepressants (TCAs) at α7 and α9α10 nicotinic acetylcholine receptors (AChRs) as well as at hippocampal α7-containing (i.e., α7*) AChRs is determined by using Ca 2+ influx and electrophysiological recordings. To determine the inhibitory mechanisms, additional functional tests and molecular docking experiments are performed. The results established that TCAs (a) inhibit Ca 2+ influx in GH3-α7 cells with the following potency (IC 50 in μM) rank: amitriptyline (2.7 ± 0.3) > doxepin (5.9 ± 1.1) ∼ imipramine (6.6 ± 1.0). Interestingly, imipramine inhibits hippocampal α7* AChRs (42.2 ± 8.5 μM) in a noncompetitive and voltage-dependent manner, whereas it inhibits α9α10 AChRs (0.53 ± 0.05 μM) in a competitive and voltage-independent manner, and (b) inhibit [ 3 H]imipramine binding to resting α7 AChRs with the following affinity rank (IC 50 in μM): imipramine (1.6 ± 0.2) > amitriptyline (2.4 ± 0.3) > doxepin (4.9 ± 0.6), whereas imipramine's affinity was no significantly different to that for the desensitized state. The molecular docking and functional results support the notion that imipramine noncompetitively inhibits α7 AChRs by interacting with two overlapping luminal sites, whereas it competitively inhibits α9α10 AChRs by interacting with the orthosteric sites. Collectively our data indicate that TCAs inhibit α7, α9α10, and hippocampal α7* AChRs at clinically relevant concentrations and by different mechanisms of action.",
keywords = "Electrophysiology, Hippocampal neurons, Mechanisms of inhibition, Tricyclic antidepressants, α7 and α9α10 nicotinic acetylcholine receptors",
author = "Arias, {Hugo R.} and Elizabeth V{\'a}zquez-G{\'o}mez and Andy Hern{\'a}ndez-Abrego and Sof{\'i}a Gallino and Dominik Feuerbach and Ortells, {Marcelo O.} and Elgoyhen, {Ana Bel{\'e}n} and Jes{\'u}s Garc{\'i}a-Colunga",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.biocel.2018.04.017",
language = "English",
volume = "100",
pages = "1--10",
journal = "International Journal of Biochemistry and Cell Biology",
issn = "1357-2725",

}

Tricyclic antidepressants inhibit hippocampal α7* and α9α10 nicotinic acetylcholine receptors by different mechanisms. / Arias, Hugo R.; Vázquez-Gómez, Elizabeth; Hernández-Abrego, Andy; Gallino, Sofía; Feuerbach, Dominik; Ortells, Marcelo O.; Elgoyhen, Ana Belén; García-Colunga, Jesús.

In: International Journal of Biochemistry and Cell Biology, Vol. 100, 01.07.2018, p. 1-10.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tricyclic antidepressants inhibit hippocampal α7* and α9α10 nicotinic acetylcholine receptors by different mechanisms

AU - Arias, Hugo R.

AU - Vázquez-Gómez, Elizabeth

AU - Hernández-Abrego, Andy

AU - Gallino, Sofía

AU - Feuerbach, Dominik

AU - Ortells, Marcelo O.

AU - Elgoyhen, Ana Belén

AU - García-Colunga, Jesús

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The activity of tricyclic antidepressants (TCAs) at α7 and α9α10 nicotinic acetylcholine receptors (AChRs) as well as at hippocampal α7-containing (i.e., α7*) AChRs is determined by using Ca 2+ influx and electrophysiological recordings. To determine the inhibitory mechanisms, additional functional tests and molecular docking experiments are performed. The results established that TCAs (a) inhibit Ca 2+ influx in GH3-α7 cells with the following potency (IC 50 in μM) rank: amitriptyline (2.7 ± 0.3) > doxepin (5.9 ± 1.1) ∼ imipramine (6.6 ± 1.0). Interestingly, imipramine inhibits hippocampal α7* AChRs (42.2 ± 8.5 μM) in a noncompetitive and voltage-dependent manner, whereas it inhibits α9α10 AChRs (0.53 ± 0.05 μM) in a competitive and voltage-independent manner, and (b) inhibit [ 3 H]imipramine binding to resting α7 AChRs with the following affinity rank (IC 50 in μM): imipramine (1.6 ± 0.2) > amitriptyline (2.4 ± 0.3) > doxepin (4.9 ± 0.6), whereas imipramine's affinity was no significantly different to that for the desensitized state. The molecular docking and functional results support the notion that imipramine noncompetitively inhibits α7 AChRs by interacting with two overlapping luminal sites, whereas it competitively inhibits α9α10 AChRs by interacting with the orthosteric sites. Collectively our data indicate that TCAs inhibit α7, α9α10, and hippocampal α7* AChRs at clinically relevant concentrations and by different mechanisms of action.

AB - The activity of tricyclic antidepressants (TCAs) at α7 and α9α10 nicotinic acetylcholine receptors (AChRs) as well as at hippocampal α7-containing (i.e., α7*) AChRs is determined by using Ca 2+ influx and electrophysiological recordings. To determine the inhibitory mechanisms, additional functional tests and molecular docking experiments are performed. The results established that TCAs (a) inhibit Ca 2+ influx in GH3-α7 cells with the following potency (IC 50 in μM) rank: amitriptyline (2.7 ± 0.3) > doxepin (5.9 ± 1.1) ∼ imipramine (6.6 ± 1.0). Interestingly, imipramine inhibits hippocampal α7* AChRs (42.2 ± 8.5 μM) in a noncompetitive and voltage-dependent manner, whereas it inhibits α9α10 AChRs (0.53 ± 0.05 μM) in a competitive and voltage-independent manner, and (b) inhibit [ 3 H]imipramine binding to resting α7 AChRs with the following affinity rank (IC 50 in μM): imipramine (1.6 ± 0.2) > amitriptyline (2.4 ± 0.3) > doxepin (4.9 ± 0.6), whereas imipramine's affinity was no significantly different to that for the desensitized state. The molecular docking and functional results support the notion that imipramine noncompetitively inhibits α7 AChRs by interacting with two overlapping luminal sites, whereas it competitively inhibits α9α10 AChRs by interacting with the orthosteric sites. Collectively our data indicate that TCAs inhibit α7, α9α10, and hippocampal α7* AChRs at clinically relevant concentrations and by different mechanisms of action.

KW - Electrophysiology

KW - Hippocampal neurons

KW - Mechanisms of inhibition

KW - Tricyclic antidepressants

KW - α7 and α9α10 nicotinic acetylcholine receptors

UR - http://www.scopus.com/inward/record.url?scp=85046666947&partnerID=8YFLogxK

U2 - 10.1016/j.biocel.2018.04.017

DO - 10.1016/j.biocel.2018.04.017

M3 - Article

C2 - 29704625

AN - SCOPUS:85046666947

VL - 100

SP - 1

EP - 10

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

SN - 1357-2725

ER -